Recent developments in medical research have highlighted a promising stem cell treatment for Type 1 diabetes, with significant outcomes reported from clinical trials. In a study presented at a recent scientific meeting, 12 participants with the most severe form of Type 1 diabetes received a single infusion of stem cell-derived pancreatic islet cells. One year after the treatment, 10 of the 12 participants no longer required insulin injections, as their bodies began producing insulin naturally. The trial, conducted over six months with follow-up data extending to a year, showed sustained insulin production without the need for immunosuppressive drugs, a notable advancement. The treatment involves pluripotent stem cells engineered to restore pancreatic islet cell function, improving glucose regulation in the 14 participants involved in related studies. This follows earlier reports of a woman achieving insulin independence after a single dose of experimental stem cells. The findings, shared across multiple research platforms, suggest a potential global rollout, with researchers indicating this could revolutionize Type 1 diabetes management. The success rate of 83% (10 out of 12) in the initial group has sparked interest, with plans for further trials to validate the results across larger populations.
34news.online
34news.online
